Gene Therapy Program

• To Further Advance Gene Therapy Research, Industry Pioneer Jim Wilson is Forming Two Independent Companies Dedicated to Genetic Medicine

  Today, James Wilson, MD, PhD, director of the Gene Therapy Program ("GTP"), Rose H. Weiss Professor and Director of the Orphan Disease Center, and professor in the Departments of Medicine and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania ("Penn"), announced that he will be founding two new companies formed in part from a transition of Penn GTP functions to the new companies.

• Penn Medicine at the American Society of Gene and Cell Therapy 27th Annual Meeting

  Researchers from the Gene Therapy Program (GTP) at the Perelman School of Medicine at the University of Pennsylvania presented ten research abstracts, two invited talks, and a workshop presentation highlighting translational science and discovery research on gene therapy, gene editing, and adeno-associated virus (AAV) vector technology.

• FDA Approval for New Attempt to Treat Liver Ailment in Babies

  iECURE, a gene editing company started by University of Pennsylvania scientist Dr. Jim Wilson, has received FDA approval to test a form of gene editing in infants for the first time in the United States.

Use arrow keys to view news